Intraarterial infusion of GP IIb/IIIa inhibitor tirofiban at the occlusion site may be a reasonable therapeutic option since the major components of thrombi in situ of ICAS are rich in platelets and fibrin. The gene discussed is ITGA2B; the disease is familial isolated congenital asplenia.